Insider Selling: Medpace (NASDAQ:MEDP) CEO Sells 23,862 Shares of Stock

Medpace Holdings, Inc. (NASDAQ:MEDP) CEO August Troendle sold 23,862 shares of the business’s stock in a transaction on Wednesday, November 19th. The stock was sold at an average price of $592.07, for a total transaction of $14,127,974.34. Following the transaction, the chief executive officer owned 862,315 shares in the company, valued at approximately $510,550,842.05. The trade was a 2.69% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website.

Medpace Price Performance

MEDP stock traded down $6.02 during trading hours on Thursday, reaching $586.16. The stock had a trading volume of 137,221 shares, compared to its average volume of 412,888. The stock has a 50-day simple moving average of $545.66 and a 200 day simple moving average of $429.61. Medpace Holdings, Inc. has a fifty-two week low of $250.05 and a fifty-two week high of $625.00. The stock has a market capitalization of $16.51 billion, a PE ratio of 40.99, a price-to-earnings-growth ratio of 2.67 and a beta of 1.42.

Medpace (NASDAQ:MEDP) last released its quarterly earnings data on Wednesday, October 22nd. The company reported $3.86 earnings per share for the quarter, topping the consensus estimate of $3.50 by $0.36. The company had revenue of $659.90 million for the quarter, compared to analyst estimates of $640.49 million. Medpace had a net margin of 18.36% and a return on equity of 91.88%. During the same period in the previous year, the business earned $3.01 EPS. Medpace’s revenue for the quarter was up 23.7% compared to the same quarter last year. Medpace has set its FY 2025 guidance at 14.600-14.860 EPS. On average, sell-side analysts forecast that Medpace Holdings, Inc. will post 12.29 EPS for the current fiscal year.

Analysts Set New Price Targets

MEDP has been the subject of a number of recent analyst reports. Rothschild & Co Redburn cut Medpace from a “buy” rating to a “neutral” rating and raised their price objective for the company from $342.00 to $474.00 in a research report on Wednesday, September 3rd. Zacks Research raised shares of Medpace from a “hold” rating to a “strong-buy” rating in a research report on Monday, October 27th. Truist Financial set a $555.00 target price on shares of Medpace in a report on Monday, October 27th. Jefferies Financial Group increased their price target on shares of Medpace from $400.00 to $450.00 and gave the company a “hold” rating in a report on Tuesday, September 9th. Finally, Mizuho raised their price objective on shares of Medpace from $575.00 to $655.00 and gave the stock an “outperform” rating in a research report on Friday, October 24th. One investment analyst has rated the stock with a Strong Buy rating, two have assigned a Buy rating, ten have given a Hold rating and four have assigned a Sell rating to the stock. According to MarketBeat.com, the company presently has an average rating of “Hold” and a consensus target price of $487.18.

Hedge Funds Weigh In On Medpace

Several institutional investors and hedge funds have recently modified their holdings of MEDP. Ariadne Wealth Management LP acquired a new stake in Medpace in the 3rd quarter worth about $244,000. Wilmington Savings Fund Society FSB grew its position in shares of Medpace by 124.1% during the 3rd quarter. Wilmington Savings Fund Society FSB now owns 130 shares of the company’s stock worth $67,000 after purchasing an additional 72 shares in the last quarter. Caerus Investment Advisors LLC bought a new position in shares of Medpace during the third quarter worth approximately $811,000. Sunbelt Securities Inc. increased its holdings in shares of Medpace by 12.3% during the third quarter. Sunbelt Securities Inc. now owns 464 shares of the company’s stock worth $239,000 after purchasing an additional 51 shares during the period. Finally, Captrust Financial Advisors raised its position in shares of Medpace by 9.9% in the third quarter. Captrust Financial Advisors now owns 44,575 shares of the company’s stock valued at $22,919,000 after buying an additional 4,003 shares in the last quarter. 77.98% of the stock is currently owned by institutional investors and hedge funds.

About Medpace

Medpace Holdings, Inc engages in the provision of outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries. Its services include medical department, clinical trial management, data-driven feasibility, study-start-up, clinical monitoring, regulatory affairs, patient recruitment and retention, medical writing, biometrics and data sciences, pharmacovigilance, core laboratory, laboratories, clinics, and quality assurance.